# Bone Mineral Density on GLP-1 Drugs in Type 2 Diabetes: 25 Trials | This GLP A 25-trial meta-analysis found GLP-1 agonists raised lumbar spine, hip neck and total hip bone density, while pooled fracture risk was 0.80 (95% CI 0.47 to 1.36). Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-bone-density-vs-fractures Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Bone Mineral Density on GLP-1 Drugs in Type 2 Diabetes: 25 Trials Twenty-five trials found higher bone density at every site measured. The fracture interval runs from 0.47 to 1.36 — consistent with a halving and with a rise. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Fracture risk ratio, 25 trials · 1.0 · 0.47 · 1.36 · Bone density gain, grams per square centimeter · Lumbar spine · +0.07 · Hip neck · +0.05 · Total hip · +0.06 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Losing weight quickly takes bone with it, which is why the skeleton keeps coming up around this drug class and why a reader who intends to stay on one for a year has a fair reason to ask about it. A meta-analysis of twenty-five randomized trials in type 2 diabetes gathered what has actually been measured [\[1\]](https://thisglp.com/research/glp1-bone-density-vs-fractures#ref-1), and the answer separates into two parts that point in different directions — a separation worth keeping straight before any of it reaches a claim on a [seller’s page](https://thisglp.com/best). ## Density went up Bone mineral density was higher on a GLP-1 receptor agonist than in the control arms at every site measured: the lumbar spine by 0.07 g/cm² (95% CI 0.06 to 0.09, P < 0.00001), the hip neck by 0.05 g/cm² (95% CI 0.03 to 0.08, P = 0.0001) and the total hip by 0.06 g/cm² (95% CI 0.04 to 0.07, P < 0.00001). The turnover markers moved consistently with that: formation markers rose — P1NP at a standardized mean difference of 0.33 (95% CI 0.07 to 0.59), osteocalcin by 1.46 µg/L (95% CI 1.10 to 1.83), bone-specific alkaline phosphatase by 0.91 µg/L (95% CI 0.19 to 1.63) — while β-CTX, which tracks resorption, fell at a standardized mean difference of −0.34 (95% CI −0.54 to −0.14). Calcium, phosphate and total alkaline phosphatase did not move at all. ## Fractures did not answer The outcome that matters to a person rather than to a scan is whether bones break, and there the pooled risk ratio was 0.80 with a 95% confidence interval of 0.47 to 1.36 (P = 0.41). The authors summarize that as no significant association, which is accurate, but the interval is the part to read: it is compatible with fractures falling by more than half and with them rising by more than a third. That is not reassurance. It is a set of trials too small, and followed for too little time, to distinguish between those two worlds — the same problem we found where [two meta-analyses of the same six trials](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials) reached opposite conclusions. ## And the cohort is not this market Every trial pooled here enrolled people with type 2 diabetes, whose bone behaves oddly: density often reads normal or high while fracture risk is raised anyway, so density is a worse proxy in that group than in anyone else. A buyer without diabetes — most of the people reading a telehealth seller’s page — is outside the population these numbers describe. We have written before about a fracture finding that [stopped at the edge of the diabetes cohort](https://thisglp.com/research/semaglutide-fractures-diabetes-only), and this is the same boundary seen from the other side. The practical version is dull and unchanged: resistance training and enough protein are what the evidence supports for protecting lean tissue and bone during weight loss, and neither is something a seller charges for. What a seller does control is whether a clinician is reachable to raise it with, which is the gap we count in [questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs weaken bone? In these twenty-five trials bone density was higher on the drug, not lower, at the lumbar spine, hip neck and total hip. Whether that translates into fewer broken bones is not established. What does the fracture result actually say? A pooled risk ratio of 0.80 with a 95% confidence interval of 0.47 to 1.36. That spans a near-halving and a rise of more than a third, so it distinguishes nothing. Does this apply to me if I do not have diabetes? Not directly. Every trial pooled here enrolled people with type 2 diabetes, in whom bone density is a poorer guide to fracture risk than it is in anyone else. ## Sources 1. \[1\] Tan Y, et al. (2025). Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis Acta Diabetologica. [PMID 39985672](https://pubmed.ncbi.nlm.nih.gov/39985672/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)